Sexually transmitted diseases

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Despite many advances in the diagnosis and treatment of sexually transmitted diseases/infections (STDs/STIs), the epidemic continues unabated. Moreover, STDs are associated with significant social, health, and economic burdens both in the USA and worldwide. In the developing countries of the world, STDs (excluding HIV/AIDS) are the second leading cause of lost healthy life among women aged 15 to 44 years. The World Health Organization (WHO) estimated in 1999 that 340 million new cases of the four curable STDs (gonorrhea, syphilis, trichomoniasis, and chlamydia) occurred in those aged 15–49 years worldwide annually. The Institute of Medicine in their report The Hidden Epidemic: Confronting Sexually Transmitted Diseases estimated that, as of 1993, 12 million new cases of STDs were occurring annually in the USA. As a result, the USA had the highest rates of curable STDs among countries in the developed world. In fact, the Centers for Disease Control and Prevention (CDC) noted in 2009 that four of the ten most frequently reported infections in the USA were STDs (chlamydia, gonorrhea, syphilis, and HIV). In its report, the Institute of Medicine noted that the economic impact of this “hidden epidemic ” was substantial, with an estimated total cost for a selected group of major STDs and related syndromes (excluding HIV) of $10 billion in 1994.

Original languageEnglish (US)
Title of host publicationClinical Gynecology, Second Edition
PublisherCambridge University Press
Pages318-348
Number of pages31
ISBN (Print)9781139628938, 9781107040397
DOIs
StatePublished - Jan 1 2015

Fingerprint

Chlamydia
Gonorrhea
Syphilis
Sexually Transmitted Diseases
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
HIV
Economics
Centers for Disease Control and Prevention (U.S.)
Developed Countries
Developing Countries
Acquired Immunodeficiency Syndrome
Costs and Cost Analysis
Health
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sweet, R. L. (2015). Sexually transmitted diseases. In Clinical Gynecology, Second Edition (pp. 318-348). Cambridge University Press. https://doi.org/10.1017/CBO9781139628938.024

Sexually transmitted diseases. / Sweet, Richard L.

Clinical Gynecology, Second Edition. Cambridge University Press, 2015. p. 318-348.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sweet, RL 2015, Sexually transmitted diseases. in Clinical Gynecology, Second Edition. Cambridge University Press, pp. 318-348. https://doi.org/10.1017/CBO9781139628938.024
Sweet RL. Sexually transmitted diseases. In Clinical Gynecology, Second Edition. Cambridge University Press. 2015. p. 318-348 https://doi.org/10.1017/CBO9781139628938.024
Sweet, Richard L. / Sexually transmitted diseases. Clinical Gynecology, Second Edition. Cambridge University Press, 2015. pp. 318-348
@inbook{3f258389c22d450da612b73afa674a21,
title = "Sexually transmitted diseases",
abstract = "Introduction Despite many advances in the diagnosis and treatment of sexually transmitted diseases/infections (STDs/STIs), the epidemic continues unabated. Moreover, STDs are associated with significant social, health, and economic burdens both in the USA and worldwide. In the developing countries of the world, STDs (excluding HIV/AIDS) are the second leading cause of lost healthy life among women aged 15 to 44 years. The World Health Organization (WHO) estimated in 1999 that 340 million new cases of the four curable STDs (gonorrhea, syphilis, trichomoniasis, and chlamydia) occurred in those aged 15–49 years worldwide annually. The Institute of Medicine in their report The Hidden Epidemic: Confronting Sexually Transmitted Diseases estimated that, as of 1993, 12 million new cases of STDs were occurring annually in the USA. As a result, the USA had the highest rates of curable STDs among countries in the developed world. In fact, the Centers for Disease Control and Prevention (CDC) noted in 2009 that four of the ten most frequently reported infections in the USA were STDs (chlamydia, gonorrhea, syphilis, and HIV). In its report, the Institute of Medicine noted that the economic impact of this “hidden epidemic ” was substantial, with an estimated total cost for a selected group of major STDs and related syndromes (excluding HIV) of $10 billion in 1994.",
author = "Sweet, {Richard L}",
year = "2015",
month = "1",
day = "1",
doi = "10.1017/CBO9781139628938.024",
language = "English (US)",
isbn = "9781139628938",
pages = "318--348",
booktitle = "Clinical Gynecology, Second Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Sexually transmitted diseases

AU - Sweet, Richard L

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction Despite many advances in the diagnosis and treatment of sexually transmitted diseases/infections (STDs/STIs), the epidemic continues unabated. Moreover, STDs are associated with significant social, health, and economic burdens both in the USA and worldwide. In the developing countries of the world, STDs (excluding HIV/AIDS) are the second leading cause of lost healthy life among women aged 15 to 44 years. The World Health Organization (WHO) estimated in 1999 that 340 million new cases of the four curable STDs (gonorrhea, syphilis, trichomoniasis, and chlamydia) occurred in those aged 15–49 years worldwide annually. The Institute of Medicine in their report The Hidden Epidemic: Confronting Sexually Transmitted Diseases estimated that, as of 1993, 12 million new cases of STDs were occurring annually in the USA. As a result, the USA had the highest rates of curable STDs among countries in the developed world. In fact, the Centers for Disease Control and Prevention (CDC) noted in 2009 that four of the ten most frequently reported infections in the USA were STDs (chlamydia, gonorrhea, syphilis, and HIV). In its report, the Institute of Medicine noted that the economic impact of this “hidden epidemic ” was substantial, with an estimated total cost for a selected group of major STDs and related syndromes (excluding HIV) of $10 billion in 1994.

AB - Introduction Despite many advances in the diagnosis and treatment of sexually transmitted diseases/infections (STDs/STIs), the epidemic continues unabated. Moreover, STDs are associated with significant social, health, and economic burdens both in the USA and worldwide. In the developing countries of the world, STDs (excluding HIV/AIDS) are the second leading cause of lost healthy life among women aged 15 to 44 years. The World Health Organization (WHO) estimated in 1999 that 340 million new cases of the four curable STDs (gonorrhea, syphilis, trichomoniasis, and chlamydia) occurred in those aged 15–49 years worldwide annually. The Institute of Medicine in their report The Hidden Epidemic: Confronting Sexually Transmitted Diseases estimated that, as of 1993, 12 million new cases of STDs were occurring annually in the USA. As a result, the USA had the highest rates of curable STDs among countries in the developed world. In fact, the Centers for Disease Control and Prevention (CDC) noted in 2009 that four of the ten most frequently reported infections in the USA were STDs (chlamydia, gonorrhea, syphilis, and HIV). In its report, the Institute of Medicine noted that the economic impact of this “hidden epidemic ” was substantial, with an estimated total cost for a selected group of major STDs and related syndromes (excluding HIV) of $10 billion in 1994.

UR - http://www.scopus.com/inward/record.url?scp=84952948225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952948225&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139628938.024

DO - 10.1017/CBO9781139628938.024

M3 - Chapter

AN - SCOPUS:84952948225

SN - 9781139628938

SN - 9781107040397

SP - 318

EP - 348

BT - Clinical Gynecology, Second Edition

PB - Cambridge University Press

ER -